| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on June 7, 2004
From the Department of Internal Medicine, Divisions of Cardiovascular Medicine (P.F.B., Y.S., F.B.V., X.B., K.A.O., S.G., D.T.E.) and Nephrology (J.A.S.), University of Michigan Medical Center, Ann Arbor, Mich. * To whom correspondence should be addressed. E-mail: deitzman{at}umich.edu.
Background-- Methods and Results--To determine whether Gla affects the progression of atherosclerosis, mice were generated with combined deficiencies of apolipoprotein E and Gla. At 45 weeks of age, Gla-deficient mice had developed more atherosclerosis than mice with normal Gla expression (25.1±14.0 versus 12.3±9.3 mm2 of total lesion area, P<0.02). This increase in atherosclerosis was associated with the presence of increased Gb3, enhanced inducible nitric oxide synthase expression, and increased nitrotyrosine staining. Conclusions--These findings suggest that deficiency of Gla leads to increased inducible nitric oxide synthase expression and accelerated atherosclerosis.
Revised on October 6, 2004
Accepted on October 12, 2004
Peter F. Bodary PhD,
-Galactosidase A Deficiency Accelerates Atherosclerosis in Mice With Apolipoprotein E Deficiency
-Galactosidase A (Gla) deficiency leads to widespread tissue accumulation of neutral glycosphingolipids and is associated with premature vascular complications such as myocardial infarction and stroke. Glycosphingolipids have been shown to accumulate in human atherosclerotic lesions, although their role in atherogenesis is unclear.
This article has been cited by other articles:
![]() |
E. N. Glaros, W. S. Kim, K.-A. Rye, J. A. Shayman, and B. Garner Reduction of plasma glycosphingolipid levels has no impact on atherosclerosis in apolipoprotein E-null mice J. Lipid Res., August 1, 2008; 49(8): 1677 - 1681. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Shu and J. A. Shayman Caveolin-associated Accumulation of Globotriaosylceramide in the Vascular Endothelium of {alpha}-Galactosidase A Null Mice J. Biol. Chem., July 20, 2007; 282(29): 20960 - 20967. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. F. Moore, M. P. Gelderman, P. A. Ferreira, S. R. Fuhrmann, H. Yi, A. Elkahloun, L. M. Lix, R. O. Brady, R. Schiffmann, and E. Goldin Genomic abnormalities of the murine model of Fabry disease after disease-related perturbation, a systems biology approach PNAS, May 8, 2007; 104(19): 8065 - 8070. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Kaneski, D. F. Moore, M. Ries, G. C. Zirzow, and R. Schiffmann Myeloperoxidase predicts risk of vasculopathic events in hemizgygous males with Fabry disease Neurology, December 12, 2006; 67(11): 2045 - 2047. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Shen, P. F. Bodary, F. B. Vargas, J. W. Homeister, D. Gordon, K. A. Ostenso, J. A. Shayman, and D. T. Eitzman {alpha}-Galactosidase A Deficiency Leads to Increased Tissue Fibrin Deposition and Thrombosis in Mice Homozygous for the Factor V Leiden Mutation Stroke, April 1, 2006; 37(4): 1106 - 1108. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Shu, H. S. Murphy, L. Cooling, and J. A. Shayman An In Vitro Model of Fabry Disease J. Am. Soc. Nephrol., September 1, 2005; 16(9): 2636 - 2645. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2005 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |